KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Current Taxes (2016 - 2020)

Supernus Pharmaceuticals (SUPN) has disclosed Current Taxes for 5 consecutive years, with $25.1 million as the latest value for Q2 2020.

  • On a quarterly basis, Current Taxes rose 836.87% to $25.1 million in Q2 2020 year-over-year; TTM through Jun 2020 was $25.1 million, a 836.87% increase, with the full-year FY2019 number at $2.4 million, down 80.26% from a year prior.
  • Current Taxes was $25.1 million for Q2 2020 at Supernus Pharmaceuticals, up from $9.1 million in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $25.1 million in Q2 2020 to a low of $7000.0 in Q4 2016.
  • A 5-year average of $8.9 million and a median of $7.5 million in 2017 define the central range for Current Taxes.
  • Peak YoY movement for Current Taxes: soared 227585.71% in 2017, then tumbled 80.26% in 2019.
  • Supernus Pharmaceuticals' Current Taxes stood at $7000.0 in 2016, then skyrocketed by 227585.71% to $15.9 million in 2017, then dropped by 22.34% to $12.4 million in 2018, then crashed by 80.26% to $2.4 million in 2019, then soared by 925.46% to $25.1 million in 2020.
  • Per Business Quant, the three most recent readings for SUPN's Current Taxes are $25.1 million (Q2 2020), $9.1 million (Q1 2020), and $2.4 million (Q4 2019).